Lab/Morphology Flashcards
Morphological and clinical features of Alder Reilly
Pathophys: Lack lysome enzyme needed to degrade mucopolysaccharides
Clinical presentation: dysmorphism, skeletal dysplasia, HSM, corneal opacities
Morphology: azurophilic cytoplasmic inclusions in ALL leukocytes (including lymphocytes) of patient with accumulated mucopolysaccharidosis
-NEVER has dhole bodies
Alder…ALL WBCs
reiLLy … lacks lysozyme
Morphological and clinical features of Chediak Higashi
Pathophys: fusion of primary and secondary lysosomal granules leading to poor fxn in killing phagocytized bacteria
Clinical presentation: partial oculocutaneous albinism, recurrent infections, neuropathy, photophobia, nystagmus, HSM, pancytopenia, LAN, Increased risk of EBV-linked lymphomas
Morphology: Giant azurophilic (or grey) granules within granulocytes (neutrophils, eosinophils).
HiGashi…all grans
Morphological features of MYH9 disorder
Giant platelets and Dohle-like bodies in neutrophils (also seen in monos, other granulocyte and lymphocytes)
Seen in all forms except Epstein.
Conditions with pseudo-pelgerization
MDS
AML
CMML
Drug effect (Tac)
Forward scatter
Size
Side scatter
Granularity
Antigens that make up Rh
C,D, E, c, e
Clinically Significant
Antigens that make up Kell
K,k, Kpa,Kpb, Jsa,Jsb
Clinically Significant
Antigens that make up Duffy
Fya, Fyb
Clinically Significant
Antigens that make up Kidd
Jka, Jkb
Clinically Significant
Antigens that make up Lewis
Lea,Leb
Clinically Insignificant
Antigens that make up MNS
M,N,S,s,U
Clinically Significant=S,s,U
Clinically Insignificant-M,N
Antigens that make up I
i,I
Clinically Insignificant
Antigens that make up Iutheran
Lua,Lub
Clinically Insignificant
Antigens that make up XG
Xga, Xgb
Clinically Insignificant
Define a Bethesda unit
The amount of inhibitor that will neutralize 50% of 1U of factor VIII:C in normal plasma after incubation for 120 mins at 37 degrees.
Reciprocal of the dilution of patient plasma that inhibits 50% of FVIII activity in an equal volume of normal plasma
What is on the Y and X axes of a Kaplan-Meier Survival Curve?
X = time Y = percent survival
Causes of megablastosis
- Vitamin B12 def
- Folate def
- Copper deficiency
- Drugs: HU, MTX, phenytoin Azathioprine, HIV drugs
- MDS
- Parvovirus B19
- Congenital Dyserythropoeitic Anemia
- Inherited pyrimidine synthesis disorders: orotic aciduria
Causes of ringed sideroblasts
MDS-RS Congenital RS Alcohol Drugs (Isoniazid, chloramphenicol, linezolid) Hypothermia Copper deficiency Lead poisoning Zn excess
5 iron granules per erythroid precursor, Take up ⅓ of nucleus. Prussian blue stain!
How do epigenetic drugs work? What are a few examples?
Epigenetic drugs work by regulating chromatin. The 2 major components of chromatin are DNA and histone proteins.
Epigenetic drugs work by:
- DNA methylation
- Histone acetylation and methylation
Examples:
HDAC inhibitors: Vorinostat (CTCL), Panobinostat (MM), Romidepsin (CTCL)
Hypomethylating agents: AZA, decitabine
Diagnostic criteria of TRALI
Acute onset (during or within 6 hours of transfusion)
Hypoxemia* (PaO2/FiO2 ≤300 or SpO2 <90% on room air or other clinical evidence of hypoxemia)
Bilateral infiltrates on frontal CXR
No evidence of circulatory overload/left atrial hypertension
No pre-existing ALI/ARDS before transfusion
Mechanism of TRALI (two-hit hypothesis)
- Neutrophil sequestration and priming – The first hit involves neutrophil sequestration and priming (sensitive neutrophils) in the lung microvasculature, due to recipient factors such as endothelial injury.
- Neutrophil activation – The second hit is activation of recipient neutrophils by a factor in the blood product. Activation is associated with the release from neutrophils of cytokines, reactive oxygen species, oxidases, and proteases that damage the pulmonary capillary endothelium
MOST COMMON ANTIBODY: HNA-3a
Most common antibody involved in TRALI
MOST COMMON ANTIBODY: HNA-3a
Ways to minimize TRALI
- Not using female plasma for FFP (just for fractionated products)
- Using male plasma to resuspend platelets
- Only males or nulliparous F for apheresis plasma/platelet collections